Exhibit 99.1
Lexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance
Kelowna, British Columbia September 7, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria), a drug delivery platform innovator, announces strategic additions to its patent portfolio.
Three new Australian patents were granted to Lexaria by the Australian Patent Office, bringing the Companys worldwide patent portfolio to eight issued patents: four each in the US and Australia. All eight patents are within Lexarias first patent family, Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof, and significantly strengthen Lexarias intellectual property claims in the US and Australia. The three new Australian patents are projected to expire on June 10, 2035.
Meanwhile the US Patent & Trademark Office has issued two new Notices of Allowance for pending patent applications and the Company expects to receive corresponding US issued patents prior to year-end 2018. The Company is concurrently pursuing accelerated examination in Australia based on these US Notices of Allowance and expects two new Australian patents to also be issued prior to year-end 2018. If issued in both the US and Australia, the Company will then hold twelve issued patents within its first patent family and continues to pursue claims in corresponding pending applications within this first patent family around the world.
Lexaria has been working throughout 2018 to expand its patent portfolio as a result of positive developments from its many research projects. The Company defines a patent family as a set of related applications directed to a new particular invention, and that may include US provisional applications, PCT applications, national stage applications including the US, continuations thereof, as well as issued/granted patents.
On April 11, 2018 Lexaria reported that it was then managing six patent families. Lexaria has now filed a total of over 50 patent applications across nine current patent families. The Company is preparing at least seven additional patent applications that will each form the basis for a separate patent family. Lexaria expects to have filed the seven new patent applications before the end of 2018 and will then be managing sixteen patent families. The Company expects many patents to be granted within each of these patent families.
With over 50 patent applications filed worldwide across nine patent families and at least seven more patent families planned, the Company will disclose material patent filings and issuances, but not each patent-related development.
About Lexaria
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has eight patents granted in the USA and in Australia
and has filed over 50 patent applications worldwide across nine patent families.
Lexarias technology provides increases in intestinal absorption rates; more
rapid delivery to the bloodstream; and important taste-masking benefits, for
orally administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp | |
and on Facebook https://www.facebook.com/lexariabioscience/ |
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience
Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. Scientific R&D is often
unpredictable and unanticipated results could emerge from any study and have a
material impact as can any results that cannot be reproduced in subsequent
testing. There is no assurance that any planned corporate activity, scientific
study, R&D, business venture, or initiative will be pursued, or if pursued,
will be successful. There is no assurance that any of Lexarias postulated uses,
benefits, or advantages for the patented and patent-pending technology will in
fact be realized in any manner or in any part. No statement herein has been
evaluated by the Food and Drug Administration (FDA). TurboCBDTM,
DehydraTECHTM technology and ViPovaTM products are not
intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.